These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 11501202)
1. Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk? Gilleece Y; Nelson M J HIV Ther; 2001 May; 6(2):37-9. PubMed ID: 11501202 [No Abstract] [Full Text] [Related]
2. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy. Smith D J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199 [No Abstract] [Full Text] [Related]
3. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD; AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520 [TBL] [Abstract][Full Text] [Related]
4. Effects of sex and race on lipodystrophy pathogenesis. Nolan D; Mallal S J HIV Ther; 2001 May; 6(2):32-6. PubMed ID: 11501201 [No Abstract] [Full Text] [Related]
5. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Calza L; Manfredi R; Chiodo F J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323 [TBL] [Abstract][Full Text] [Related]
9. HIV, HAART, and hyperlipidemia: balancing the effects. Sherer R J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S123-9. PubMed ID: 14703941 [No Abstract] [Full Text] [Related]
10. Antiretrovirals and cardiovascular disease: is HAART bad for your heart? Fichtenbaum CJ AIDS Clin Care; 2003 Aug; 15(8):69-73, 76. PubMed ID: 12945527 [No Abstract] [Full Text] [Related]
11. Substitution for protease inhibitors in HIV therapy. Mikhail E N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602 [No Abstract] [Full Text] [Related]
12. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Grover SA; Coupal L; Gilmore N; Mukherjee J Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096 [TBL] [Abstract][Full Text] [Related]
14. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk among HIV-positive patients on antiretroviral therapy. Aberg JA J Int Assoc Physicians AIDS Care (Chic); 2003 Sep; 2 Suppl 2():S24-39. PubMed ID: 14569635 [TBL] [Abstract][Full Text] [Related]
16. Sex differences in adverse reactions to antiretroviral drugs. Ofotokun I; Pomeroy C Top HIV Med; 2003; 11(2):55-9. PubMed ID: 12717043 [TBL] [Abstract][Full Text] [Related]
17. Dyslipidaemia and cardiovascular risk in HIV infection. Kulasekaram R; Peters BS; Wierzbicki AS Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691 [TBL] [Abstract][Full Text] [Related]
18. HAART-associated body habitus and metabolic changes, Part 2. Liss M; Boyle BA AIDS Read; 2000 Dec; 10(12):688-91. PubMed ID: 11189733 [No Abstract] [Full Text] [Related]